Edesa Biotech (EDSA) Non Operating Interest Expenses (2021 - 2022)
Edesa Biotech's (EDSA) quarterly Non Operating Interest Expenses came in at $4.6 million in Q1 2022, down 51.89% year-over-year from $9.5 million in Q1 2021, and down 51.89% quarter-over-quarter from $9.5 million in Q1 2021.
Powered by 
Analysis
Edesa Biotech (EDSA) Non Operating Interest Expenses (2021 - 2022) Analysis & Trends
Edesa Biotech has disclosed Non Operating Interest Expenses across 2 years of filings, most recently posting $4.6 million for Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Edesa Biotech | 43.87 Mn | 43.87 Mn | - | - |